Mitomics is a Canadian diagnostics company built around mitochondrial DNA–based disease detection. Public company materials describe a portfolio of blood-based and tissue-based tests intended to improve cancer detection and prognosis, including work in prostate cancer and additional development programs in ovarian, lung, liver, pancreatic, stomach cancers, and endometriosis. The company’s platform is centered on its proprietary Mitomic technology.